Stryker Corporation reported a challenging first quarter, with organic sales growth of 2.4% globally, significantly impacted by a late-quarter cyber incident. Adjusted earnings per share fell to $2.60, an 8.5% decline from the previous year, primarily due to limited sales growth, lost manufacturing absorption, and increased interest expenses. Despite these setbacks, management maintained full-year guidance for organic net sales growth of 8%-9.5% and adjusted EPS between $14.90 and $15.10, anticipating a recovery in the latter half of the year as operations normalize.
The cyber incident not only disrupted production but also delayed revenue recognition, revealing vulnerabilities in operational resilience. However, Stryker’s capital order book remains robust, and demand fundamentals are solid across markets, suggesting that the company can rebound effectively. The introduction of the new Orthotech segment aims to streamline operations and enhance innovation, while the recent acquisition of Amplitude Vascular Systems is expected to bolster its cardiovascular offerings.
For market professionals, the key takeaway is that while Stryker faces short-term challenges, its strategic initiatives and strong order backlog position it for a recovery, making it a stock to watch as operational stability returns.
Source: fool.com